fda glp-1 crackdown news The is cracking down on ‘misleading’ compounded GLP-1s from telehealth companies., Compounded weight loss drugs are not FDA-approved, which means the agency does not review their safety, FDA cracks down on online

The new weight management offering is designed to support women struggling with conditions like Polycystic Ovary Syndrome (PCOS), endometriosis, and menopause

Adult people (18 years) with a diagnosis of obesity (body mass index30 kg/m2) or T2DM (ICD-10-CM: E11) between 2018 and 2024 were subdivided in two mutually exclusive cohorts: (1) GLP-1 RA Users

Diabetes leads to a significantly accelerated incidence of various related macrovascular complications, including peripheral vascular disease and cardiovascular disease (the most common cause of mortality in diabetes), as well as microvascular complications such as kidney disease and retinopathy

GLP-1 agonists have shown promise in easing symptoms in obese arthritis patients

The supplier will showcase its latest solutions to help manufacturers meet evolving guidelines and consumer demands.